# FIGHT-207 (NCT03822117)

> Efficacy and Safety of Pemigatinib in Previously Treated Locally Advanced/Metastatic or Surgically Unresectable Solid Tumor Malignancies Harboring Activating FGFR Mutations or Translocations (FIGHT-207)

No report yet. It can be ordered.

- Drugs tested: pemigatinib
- Indication: previously treated solid tumors with activating FGFR1-FGFR3 alterations

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT03822117
- Phase: PHASE2
- Status: TERMINATED
- Sponsor: Incyte Corporation
- Conditions: Solid Tumor Malignancy
- Interventions: Pemigatinib
- Enrollment: 111
- Primary outcome: Objective Response Rate (ORR), Defined as the Percentage of Participants With a Best Overall Response of Complete Response (CR) or Partial Response (PR) Based on RECIST v1.1 or RANO, in Participants With FGFR1-3 In-frame Fusions or FGFR2 Arrangements
- Primary outcome: ORR, Defined as the Percentage of Participants With a Best Overall Response of CR or PR Based on RECIST v1.1 or RANO, in Participants With Known or Likely Activating FGFR1-3 Mutations

## Indexed commentary on FIGHT-207 so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- 4 posts on X
- 1 YouTube video

## Order

Focused, $750 at most (a smaller delivered size costs its own price): https://www.erudio.com/contact?report=fight-207-nct03822117